The Bloom #179 Free Edition building the infrastructure

Thank you to everyone who filled in the Global Psychedelic Survey! In total, the survey got nearly 9000 responses. I'm expecting some exciting results from the survey in the coming year(s).

Psychedelic research has been relatively slow.

One area that I'm particularly interested in, the health economics of psychedelics (put more bluntly: will insurance want to pay for them), was bolstered by a comparative analysis of ketamine versus ECT (showing savings for ketamine).

We also got back more detailed information on different administrations' routes of LSD (all being 80 %+ 'available'). And a 6! hour infusion of DMT (at a relatively low dose) went well, providing a necessary check-box before trials in stroke recovery patients.

Floris - Founder of Blossom

ps Next week, Wednesday (June 4th, 11am MST / 1pm EST), the team at Delphi (where I spent part of my working hours working on the infrastructure of psychedelics as medicines) will hold an inaugural Delphi Insight Session. Lia Mix will discuss the broader psychedelic landscape and highlight the work we've been doing. The presentation will be 30 minutes and (I believe) a perfect warm-up to Psychedelic Science. Register here for free.

​

Latest Psychedelic Research

1 Impact analysis of expanded access to ketamine for treatment-resistant depression​

This population-level Markov simulation study (n=350,000 initial patients + 11,296 annually) models the economic impacts of intravenous ketamine versus ECT for treatment-resistant depression over 5 years. The model projects annual societal savings of $828.2 million ($95.3M to patients, $743.7M to payers) with expanded ketamine access, though with an added $10.8M annual caregiver burden.

Also see this safety study on esketamine in Europe​

2 Safety, Pharmacokinetics, and Pharmacodynamics of a 6-h DMT Infusion in Healthy Volunteers​

This randomised, double-blind, placebo-controlled single ascending dose study (n=29) tested prolonged intravenous DMT administration (30-s bolus (1.5-7.5mg) + 6-h infusion (4.4-33.3nl/ml)) in healthy volunteers. It found the treatment to be safe, with only mild, self-limiting adverse events, and observed mild psychedelic effects, reduced attention and stability, and decreased occipital alpha EEG power at higher doses, supporting further investigation in stroke recovery contexts.

3 Absolute Oral Bioavailability and Bioequivalence of LSD Base and Tartrate in a Double-Blind, Placebo-Controlled, Crossover Study​

This randomized, double-blind, placebo-controlled crossover study (n=20) tests the bioequivalence and oral bioavailability of LSD base and tartrate in various formulations (ethanolic solution, watery solution, dissolvable tablet, and IV). All oral formulations were bioequivalent with 80% absolute oral bioavailability. IV LSD produced stronger subjective effects, including more ego dissolution and anxiety.

More Research

• ​Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa​

New on Blossom

1 Psychedelic Landscape – Request for Feedback​

This page has been updated with your feedback!

For the past six years, Blossom has tracked all psychedelic research and distilled the findings for researchers, clinicians and the curious. Along the way, we noticed a glaring gap: knowing what the science says is only half the story—understanding who can turn that science into real-world impact is the other half. Today, we are closing that gap with the first public draft of our Psychedelic Landscape Map.

Please review it on the site and send me your feedback.

3 Psychedelic Research Links 2025​

A comprehensive overview of all psychedelic research that has come out this year. We cover the research per month and provide a one-sentence summary for each new publication. After the full summary is added, a link to Blossom's review is added to the papers included in our database.
​

Spotlight

1 D​elphi Insight Session (Event)

June 4th at 11am MST / 1pm EST / 10am PST / 7pm CEST

Join me for the inaugural Delphi Insight Session, where Lia Mix will share what Delphi has been actively working on and present our perspective on the crucial elements needed for the successful and responsible development of the psychedelic landscape.

In 30 minutes, we'll provide an overview of the current environment, discuss key challenges and opportunities (especially in light of recent regulatory discussions), and outline the strategic approaches we believe are vital for all stakeholders, including investors, researchers, policymakers, and practitioners. This is an opportunity to understand how Delphi is working to foster clarity and strategic partnerships in this dynamic field.

​Register here for free.

Molenvaart 76, Anna Paulowna, NH 1761AL
​Unsubscribe · Preferences​